Form 8-K - Current report:
SEC Accession No. 0001689813-21-000072
Filing Date
2021-04-08
Accepted
2021-04-08 16:43:43
Documents
15
Period of Report
2021-04-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20210407.htm   iXBRL 8-K 32350
2 EX-99.1 a2021q1bhvnnetsalespre-ann.htm EX-99.1 21807
  Complete submission text file 0001689813-21-000072.txt   201875

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20210407.xsd EX-101.SCH 2441
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bhvn-20210407_cal.xml EX-101.CAL 722
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bhvn-20210407_def.xml EX-101.DEF 1655
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20210407_lab.xml EX-101.LAB 23938
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20210407_pre.xml EX-101.PRE 12646
8 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20210407_htm.xml XML 10496
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 21815320
SIC: 2834 Pharmaceutical Preparations